(Q42984790)

12 November 2017

title

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial (English)

1 reference

12 November 2017

1 reference

8

Seizaburo Kashiwagi

1 reference

12 November 2017

Hideyuki Nomura

1

1 reference

12 November 2017

Suketo Sou

2

1 reference

12 November 2017

Hironori Tanimoto

3

1 reference

12 November 2017

Takashi Nagahama

4

1 reference

12 November 2017

Yoichi Kimura

5

1 reference

12 November 2017

Jun Hayashi

6

1 reference

12 November 2017

Hiromi Ishibashi

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

12 November 2017

1 reference

12 November 2017

volume

39

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

1213-1219

1 reference

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

12 November 2017

cites work

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

7 January 2021

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

1 reference

7 January 2021

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

1 reference

7 January 2021

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

7 January 2021

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

1 reference

7 January 2021

Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

7 January 2021

Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial

1 reference

7 January 2021

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

1 reference

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

7 January 2021

Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick

1 reference

7 January 2021

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study

1 reference

7 January 2021

Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay

1 reference

7 January 2021

Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20196

1 reference

12 November 2017

1 reference